Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis
Protocol No. | PHO-COG-ANHL2121 | Scope | National |
---|---|---|---|
Principal Investigator | Ross, Anthony | Treatment Type | Treatment |
Age Group | Adults and Children | Phase | Phase II |
Protocol No. | PHO-COG-ANHL2121 | Scope | National |
---|---|---|---|
Principal Investigator | Ross, Anthony | Treatment Type | Treatment |
Age Group | Adults and Children | Phase | Phase II |
Peyton Bohle BS
webbpe@iu.edu